QIAGEN N.V. (QIA) Barclays Discloses 9.16% Voting Rights

Luxinva S.A., backed by Abu Dhabi Investment Authority, will advise on a €46.50 per share takeover offer for QIAGEN N.V., valuing it at €10.8B. The deal, led by EQT Private Equity, includes a 40.3% premium and is subject to conditions. QIAGEN specializes in molecular diagnostics and serves over 500,000 customers.

QIAGEN N.V. agreed to a €46.50-per-share takeover by Crown NL Bidco B.V. The deal, pending regulatory approval, would take QIAGEN private, potentially leading to delisting and governance changes. The agreement includes exclusivity provisions and risk-sharing mechanisms. Shareholders face uncertainty as completion is not guaranteed.

EQT has completed a €10.8 billion take-private deal for Qiagen, a biotech company. The transaction is notable for its size and impact on the private equity and biotech sectors.

Qiagen NV has accepted a buyout offer from EQT at EUR 46.50 per share. Qiagen is a prominent company in life sciences, specializing in sample preparation, analytics, and clinical diagnostics.

EQT, with partners, agreed to buy Qiagen for €9.6B ($10.78B), offering €46.50/share, an 8.6% premium. The deal, valued at $12.1B, is expected to close in mid-2027. Qiagen's board approved the offer, ending years of takeover speculation. Qiagen supplies molecular testing technologies, attracting private-equity interest.

Qiagen has agreed to an all-cash takeover offer from EQT XI fund, valuing the company at $12.1bn, including debt. The $40.3% premium offer is supported by Qiagen's board, which sees private ownership as beneficial for growth. The deal is expected to close in mid-2027, pending shareholder approval.